Table 3.
Proportion of study participants reporting systemic symptoms 0–14 days following COVID-19 vaccination and related healthcare utilization, by dose.
|
Characteristics |
Dose 1 |
Dose 2 |
||||||
|---|---|---|---|---|---|---|---|---|
|
KPSEM reports, row % |
Relevant medical encounter¶ |
KPSEM reports, row% |
Relevant medical encounter¶ | |||||
| Any systemic symptom* | P value† | Sought care§ | Any systemic symptom* | P value† | Sought care§ | |||
| Total N | 2,381 (38 %) | 129 (5 %) | 34 (1 %) | 1,198 (35 %) | 59 (5 %) | 23 (2 %) | ||
| Age, years | 0.003 | 0.171 | ||||||
| 5 | 306 (34 %) | 25 (8 %) | 6 (2 %) | 182 (37 %) | 14 (8 %) | 7 (4 %) | ||
| 6 | 327 (36 %) | 19 (6 %) | 5 (2 %) | 151 (31 %) | 6 (4 %) | 1 (1 %) | ||
| 7 | 318 (36 %) | 17 (5 %) | 3 (1 %) | 170 (36 %) | 8 (5 %) | 4 (2 %) | ||
| 8 | 370 (41 %) | 22 (6 %) | 7 (1 %) | 178 (34 %) | 8 (5 %) | 6 (3 %) | ||
| 9 | 353 (39 %) | 13 (4 %) | 6 (2 %) | 166 (35 %) | 10 (6 %) | 2 (1 %) | ||
| 10 | 352 (40 %) | 21 (6 %) | 4 (1 %) | 166 (36 %) | 6 (4 %) | 2 (1 %) | ||
| 11 | 355 (40 %) | 12 (3 %) | 3 (1 %) | 185 (39 %) | 7 (4 %) | 1 (1 %) | ||
| Sex | 0.007 | 0.649 | ||||||
| Female | 1,228 (40 %) | 64 (5 %) | 21 (2 %) | 598 (36 %) | 27 (5 %) | 11 (2 %) | ||
| Male | 1,152 (37 %) | 65 (6 %) | 13 (1 %) | 600 (35 %) | 32 (5 %) | 12 (2 %) | ||
| Race/Ethnicity | <0.001 | 0.025 | ||||||
| Hispanic | 1,030 (42 %) | 65 (6 %) | 23 (2 %) | 515 (37 %) | 26 (5 %) | 9 (2 %) | ||
| Asian | 257 (32 %) | 12 (5 %) | 3 (1 %) | 131 (32 %) | 6 (5 %) | 3 (2 %) | ||
| Black | 131 (48 %) | 8 (6 %) | 0 (-) | 68 (44 %) | 8 (5 %) | 5 (7 %) | ||
| Other/Unknown | 134 (36 %) | 8 (6 %) | 2 (1 %) | 61 (30 %) | 1 (2 %) | 0 (-) | ||
| White | 674 (35 %) | 30 (4 %) | 5 (1 %) | 347 (34 %) | 13 (4 %) | 3 (1 %) | ||
| Insurance | <0.001 | 0.004 | ||||||
| Medicaid | 428 (45 %) | 31 (7 %) | 7 (2 %) | 216 (43 %) | 14 (6 %) | 7 (3 %) | ||
| Commercial | 1,953 (37 %) | 98 (5 %) | 27 (1 %) | 982 (34 %) | 45 (5 %) | 16 (2 %) | ||
| Prior COVID-19 | ||||||||
| Yes | 273 (42 %) | <0.001 | 26 (10 %) | 7 (3 %) | 143 (41 %) | <0.001 | 12 (8 %) | 5 (3 %) |
| No | 1,903 (34 %) | 103 (5 %) | 22 (1 %) | 933 (31 %) | 47 (5 %) | 16 (2 %) | ||
*Persons were identified as ever having self-reported symptoms through KPSEM if their parent or guardian responded with ‘yes’ to KPSEM for any systemic reactions in the first two weeks following vaccination.
Differences in systemic adverse event reports were compared across demographic characteristics using chi-square tests or Fisher’s exact test.
Persons identified as self-reporting seeking advice from medical professionals in response to adverse events from the COVID-19 vaccine were defined as ever having responded ‘Yes’ to the survey question asking whether they sought care for any of their symptoms in the first two weeks following vaccination.
Persons were identified as having medically attended events related to their vaccine if their parent or guardian reported having reached out to their healthcare provider via KPSEM within 14 days of receiving a Pfizer BioNTech vaccination and had evidence of a diagnosis in their medical record within 21 days of receiving a Pfizer BioNTech vaccination corresponding to the relevant adverse event specified via KPSEM (Appendix B).